Suzuki et al
Our analysis indicates that between 20 and 30 percent of annual patients stop using the drugs, particularly those focused on weight loss, and these patients regain about two-thirds of the weight they lost
Weight loss is not guaranteed and is influenced by many factors, including diet, exercise, and individual biology." The brand-reported "up to 25% body weight reduction" figure is a ceiling cited in the context of program-wide data, not a guarantee of individual outcomes
Approximately 99% of the bioavailable tirzepatide is bound to plasma albumin
Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (20202025): What the IP and Science Signal Next This article was powered by Cypris Q, an AI agent that helps R&D teams instantly synthesize insights from patents, scientific literature, and market intelligence from around the globe
Hawaii is considering a PDAB bill